1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. TOT BIOPHARM International Company Limited
  6. News
  7. Summary
    1875   HK0000545266

TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

(1875)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
3.150 HKD   -5.97%
03/24TOT Biopharm Narrows Loss on Lower Selling, R&D Expenses in 2021
MT
03/24TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/13TOT BIOPHARM International Company Limited Announces Change of Directors and Change of Composition of Board Committees
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Overseas

01/12/2022 | 02:25am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED -5.97% 3.15 Delayed Quote.-21.55%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.46% 6.691 Delayed Quote.6.61%
All news about TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
03/24TOT Biopharm Narrows Loss on Lower Selling, R&D Expenses in 2021
MT
03/24TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year E..
CI
03/13TOT BIOPHARM International Company Limited Announces Change of Directors and Change of ..
CI
03/10China Approves New Indications for TOT Biopharm's Cancer Drug
MT
01/31TOT BIOPHARM International Company Limited Announces Change of Joint Company Secretary ..
CI
01/12TOT Biopharm International Unit Grants Kexing License to Commercialize Cancer Drug Over..
MT
01/03TOT Biopharm Arm Engages MCC Unit to Construct Global R&D Center in Chinese Province
MT
2021TOT Biopharm Sells 1 Million Shares in Lumosa Therapeutics to Center Laboratories
MT
2021TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizum..
PR
2021TOT BIOPHARM International Company Limited Announces NMPA Granted Marketing Approval fo..
CI
More news
Financials
Sales 2022 330 M 49,2 M 49,2 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 1 658 M 247 M 247 M
Capi. / Sales 2022 5,02x
Capi. / Sales 2023 3,12x
Nbr of Employees 337
Free-Float 52,0%
Chart TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Duration : Period :
TOT BIOPHARM International Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,87 CNY
Average target price 4,91 CNY
Spread / Average Target 71,4%
Managers and Directors
Jun Liu CEO, Executive Director & Chief Scientific Officer
Ben Xiao Senior Finance Director
Shan Fu Non-Executive Chairman
Ming Liu Chief Medical Officer & Vice General Manager
Lan Hu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED-21.55%263
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418